News &amp; Updates

Pregnant women with inflammatory bowel disease (IBD) who used antitumour necrosis factor (anti-TNF) therapy are at reduced risk of developing gestational diabetes mellitus (GDM), reports a study.

Anti-TNFs may reduce GDM risk in pregnant women with IBD

Hormone therapy poses no glioma risk

Users of hormone therapy do not appear to be at increased risk of glioma, according to a study.

Hormone therapy poses no glioma risk

Twice-yearly depemokimab tied to fewer severe asthma exacerbations

18 Jan 2025

In the treatment of severe asthma with an eosinophilic phenotype, 6-month dosing intervals of depemokimab appears to reduce the rate of exacerbations, as shown in a phase IIIA study.

Twice-yearly depemokimab tied to fewer severe asthma exacerbations

18 Jan 2025

Quality of life gains seen with mirikizumab regardless of prior biologic failure for CD

17 Jan 2025 by

Mirikizumab helps improve health-related quality of life (HRQoL) in Crohn’s disease (CD) patients, including those who have not had success with a biologic therapy, according to data from the phase III VIVID-1 study.

Quality of life gains seen with mirikizumab regardless of prior biologic failure for CD

Opioid use decreases in first year after bariatric surgery

Bariatric surgery has reduced the number of patients using opioids by nearly 25 percent, but those with multiple opioid prescriptions are less likely to stop its use after the procedure, according to a study.

Opioid use decreases in first year after bariatric surgery

A real-world study presented at ASH 2024 shows that CD19 chimeric antigen receptor (CAR) T-cell therapy is highly effective and has an acceptable toxicity profile for individuals with transformed indolent non-Hodgkin lymphoma (tiNHL).

CAR T-cell therapy may overcome poor prognosis tied to conventional tiNHL therapies

17 Jan 2025 by

CAR T-cell therapy may overcome poor prognosis tied to conventional tiNHL therapies

17 Jan 2025

GDF-15 inhibition shows promise in cancer cachexia

The inhibition of GDF-15 with ponsegromab in patients with cancer cachexia helps promote weight gain, improve overall activity, and reduce symptoms, as shown in the results of a phase II study.

GDF-15 inhibition shows promise in cancer cachexia

Age drives retreatment in patients treated with teprotumumab

Repeat treatment is not uncommon among patients who received a full course of teprotumumab therapy for thyroid eye disease (TED), and the sole predictor of retreatment is age.

Age drives retreatment in patients treated with teprotumumab

Intravitreal anti-VEGF therapy tied to serious adverse drug reactions

Adverse drug reactions (ADRs) appear to be significantly increased following intravitreal anti-VEGF treatment, particularly cardiovascular and cerebrovascular events, according to a recent study.

Intravitreal anti-VEGF therapy tied to serious adverse drug reactions